Evidence map›Paper›PMID 30182210›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder.

E El Rassy, T Assi, Z Bakouny, N Pavlidis, J Kattan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

E El RassyDepartment of Medical Oncology, Faculty of Medicine, Hotel Dieu de France University Hospital, Saint Joseph University, Adib Ishaac Street, Beirut, Lebanon.
T AssiDepartment of Medical Oncology, Faculty of Medicine, Hotel Dieu de France University Hospital, Saint Joseph University, Adib Ishaac Street, Beirut, Lebanon. tarekassi@gmail.com.ORCID http://orcid.org/0000-0002-5579-5264
Z BakounyDepartment of Medical Oncology, Faculty of Medicine, Hotel Dieu de France University Hospital, Saint Joseph University, Adib Ishaac Street, Beirut, Lebanon.
N PavlidisUniversity of Ioannina, Niarchos Avenue, 45110, Ioannina, Greece.
J KattanDepartment of Medical Oncology, Faculty of Medicine, Hotel Dieu de France University Hospital, Saint Joseph University, Adib Ishaac Street, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic urothelial carcinoma of the bladder is a rarely curable disease. Patients receive systemic therapy with limited response rates and survival benefits. The rescue regimens of these patients who have failed first-line treatment had remained problematic until the recent advances. Several trials with novel regimens, including immune checkpoint inhibitors and targeted therapy, to salvage relapsed urothelial carcinoma of the bladder have recently been published. However, the choice of an optimal treatment regimen remains challenging in the absence of randomized trials comparing regimen sequences. Daily clinical cases provoke the question of whether there is a preferred second-line regimen. This paper provides an overview of recent trials and proposes a management algorithm based on subgroup analyses and prognostic features.

Indexed as

AlgorithmsAntineoplastic AgentsCarcinoma, Transitional CellClinical Trials as TopicHumansSalvage TherapyUrinary Bladder NeoplasmsAntineoplastic AgentsChemotherapyImmune checkpoint inhibitorSecond-lineTargeted therapyUrothelial bladder cancer

Identifiers

PMID30182210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.